Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.20, Zacks reports. The firm had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. During the same period in the prior year, the company earned ($0.51) EPS.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR traded down $1.16 during midday trading on Wednesday, reaching $7.03. 339,561 shares of the stock traded hands, compared to its average volume of 685,198. Voyager Therapeutics has a 12-month low of $6.06 and a 12-month high of $11.72. The business has a 50-day moving average of $8.39 and a two-hundred day moving average of $8.41. The stock has a market capitalization of $382.36 million, a PE ratio of -150.77 and a beta of 0.96.

Wall Street Analyst Weigh In

VYGR has been the topic of several recent research reports. Wedbush decreased their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a report on Wednesday, May 15th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Wednesday, July 31st. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.83.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.